A Phase III Study of Vinblastine vs Vinblastine plus Estramustine for Metastatic Hormone Refractory Prostatic Cancer

Abstracts/Posters/Presentations:

• Hudes G, Roth B, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Einhorn L. A Phase III Trial of Vinblastine Versus Vinblastine plus Estramustine Phosphate for Metastatic Hormone-refractory Prostate Cancer (HRPC). A Hoosier Oncology Group, Walther Cancer Institute Fox Chase Network trial: GU93-1. Accepted to the ASCO annual meeting May 17-20, 1997, Denver, CO.
• G. Hudes, E. Ross, B. Roth, A.Balsham, P. Loehrer, H. Ramsey, J. Sprandio, M. Entmacher, W. Dugan, R. Ansari, L. Einhorn. Fox Chase Cancer Center, Philadelphia, PA and Hoosier Oncology Group, Walther Cancer Institute, Indianapolis, IN. Improved Survival for Patients with Hormone-Refractory Prostate Cancer Receiving Estramustine-Based Antimicrotubule Therapy: Final Report of a Hoosier Oncology Group and Fox Chase Network Phase III Trial Comparing Vinblastine and Vinblastine Plus Oral Estramustine Phosphate GU93-1. Accepted to the ASCO annual meeting May 18-21, 2002, Orlando, FL

Manuscripts/Articles:

• Hudes G, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Einhorn L, Roth B. Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients with Hormone Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial GU93-1. J Clin Oncology Vol 17, No 10 (October), 1999:pp 3160-3166. See abstract.